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< 0.05 level. CONCLUSIONS: The likelihood of reﬁlling an
SSRI varies by the speciﬁc SSRI and may vary by age, gender,
and copayment amount. Patients are more likely to reﬁll the ﬁrst
prescriptions for sertraline or citalopram than for paroxetine.
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MENTAL HEALTH REASONS 
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Case Western Reserve University, Cleveland, OH, USA
OBJECTIVE: To examine factors associated with diagnosis of
depression at a primary care visit for reasons unrelated to depres-
sion. METHODS: We used the 1998–2000 National Ambula-
tory Medical Care Survey for ofﬁce-based physician visits. We
included visits to their primary care physician for patients with
no indication of prior episodes of depression. We excluded
patients under 15 years old and visits where the major reason
for the visit was for mental health or social problems. We created
a multivariate logistic regression model to examine which factors
were associated with a depression diagnosis. Study variables
included: age, race, sex, geographic region, urban setting,
payment source, time spent with physician, new patient, HMO
status, capitated visit, and major reason for the visit. RESULTS:
There were 18,612 patients meeting study criteria, of whom
11,365 (61%) were female, 2,037 (11%) black, 1,940 (10%)
were under age 25 and 5,629 (30%) were at least 65 years old.
A total of 234(1.5%) patients received a depression diagnosis.
Multivariate analysis showed that younger (age 15–24; OR =
0.486, p = 0.0177) and older patients (age 65+; OR = 0.517, p
< 0.0001) were less likely to receive a depression diagnosis.
Factors associated with increased likelihood of depression diag-
nosis: female (OR = 1.81, p < 0.0001), self-pay (OR = 1.64, p =
0.329), and major reason for visit a chronic problem, both
routine (OR = 2.24, p < 0.0001) and ﬂareup (OR = 1.58, p =
0.0349). There were non-signiﬁcant trends towards reduced rate
of diagnosis in blacks (OR = 0.645, p = 0.0811) and visits related
to surgery/injury(OR = 0.343, p = .0620), and towards higher
rates in the West(OR = 1.38, p = 0.0847). There was no associ-
ation between diagnosis of depression and urban setting, new
patient, capitated visit, HMO enrollment. Association of time
spent with the physician and depression diagnosis was marginal,
though statistically signiﬁcant. CONCLUSIONS: When seeing
their primary care physician for reasons unrelated to mental
health or social problems, patients who were age 25–64, female,
self-pay or visiting for a chronic illness were substantially more
likely to be diagnosed with depression.
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OBJECTIVE: Assess trends in pharmacologic treatment for
patients with bipolar disorder. METHODS: A large claims data-
base of insured individuals from October 1992 to September
2002 was analyzed to identify patients diagnosed with bipolar
disorder (ICD9-CM: 296.4x–296.8x). Treatment regimens were
examined for six-classes of psychotropics (antidepressants,
mood-stabilizers, atypical and typical antipsychotics, anxiolytics
and hypnotics). RESULTS: Of 13,407 patients, the percent
untreated remained stable around 10% over the 10-year period.
Among treated patients, about 65% received mood stabilizers
and/or antidepressants. The two agents most frequently used
were valproate (39.7%) and olanzapine (24.2%) in 2002.
Overall, mood stabilizers increased slightly from 59.5% to
64.2%, and atypical antipsychotics increased from 4.5% to
45.1% usage. Antidepressants and anxiolytics remained stable
at around 65% and 50% respectively, although the products
chosen shifted with new market introductions. Typical antipsy-
chotics decreased from 34.5% to12.4%, and hypnotics
decreased from 13.2% to around 7% usage. CONCLUSIONS:
Although about two-thirds of patients with bipolar illness receive
mood stabilizers, there continues to be opportunity for improve-
ment in pharmacotherapy. It is also important to understand out-
comes associated with changing treatment patterns for bipolar
patients.
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OBJECTIVE: Assess recent pharmacologic treatment patterns
for patients with bipolar disorder. METHODS: A large claims
database of insured individuals from October 1998 to Septem-
ber 2002 was analyzed to identify patients diagnosed with
bipolar disorder (ICD9-CM: 296.4x–296.8x). Treatment regi-
mens were examined for six-classes of psychotropics (antide-
pressants, mood-stabilizers, atypical and typical antipsychotics,
anxiolytics and hypnotics) during the year post-diagnosis. Dif-
ferences in medication use among sub-types of bipolar were
compared. RESULTS: Of 6373 patients (56.4% female, mean
age 49.2 years), 19.4% were depressed, 14.2% manic, 21.2%
mixed, and 45.1% other episodes; 9.1% didn’t receive psy-
chotropic treatment. Among treated patients, 66.0% received
antidepressants, 64.0% mood-stabilizers, 48.2% anxiolytics,
and 42.1% atypical antipsychotics. Valproate (40.3%) and olan-
zapine (22.0%) were top two most commonly prescribed psy-
chotropics. Only 22.7% received single-class therapy, 44.2%
received ≥3 classes and 19.8% received ≥5 classes of psy-
chotropics. Among depressed patients, 76.7% received antide-
pressants, 59.2% received mood-stabilizers and 39.9% received
atypical antipsychotics versus 45.4%, 71.2% and 54.4% in
manic patients, respectively. Surprisingly, 52.3% of depressed
patients received anxiolytics—the highest percentage among all
sub-types of bipolar patients. CONCLUSIONS: Pharmacother-
apy for bipolar patients is complex. Nearly half of bipolar
patients were treated with3 classes of psychotropics. Depressed
patients were more likely to receive antidepressants and anxi-
olytics but less likely to receive mood-stabilizers.
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OBJECTIVE: To examine managed-care treatment patterns for
patients diagnosed with bipolar disorder. METHODS: We exam-
ined the PharMetrics Integrated Outcomes Database of adjudi-
cated medical and pharmaceutical claims for over 3 million
patients from 11 U.S. health plans. We identiﬁed 4,455 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8),
age between 10 and 64, and 1 year of continuous eligibility prior
to and following the initial bipolar diagnosis with claims begin-
ning January 1, 1999. RESULTS: Of the 4455 bipolar patients,
80% (3555) received medication-based treatment in a 13-month
window around the index diagnosis (12 months post and 1
month pre). A total of 38% of bipolar patients used 4 or more
medications during the 13 months. On average each patient
